Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chemical treatment enhances skipping of a mutated exon in the dystrophin gene.

Nature communications - 1 Jan 2011

Nishida Atsushi, Kataoka Naoyuki, Takeshima Yasuhiro, Yagi Mariko, Awano Hiroyuki, Ota Mitsunori, Itoh Kyoko, Hagiwara Masatoshi, Matsuo Masafumi

Abstract excerpt

Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disease caused by a loss of the dystrophin protein. Control of dystrophin mRNA splicing to convert severe DMD to a milder phenotype is attracting much attention. Here we report a dystrophinopathy patient who has a point mutation in exon 31 of the dystrophin gene. Although the mutation generates a stop codon, a small amount of internally deleted, but...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chlorocebus aethiops
Share to Codon, Nonsense

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dystrophin

Share to Muscular Dystrophy, Duchenne

Share to Point Mutation

Share to RNA Splicing

Share to Sequence Deletion

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 21556062
DOI: 10.1038/ncomms1306
PMCID: PMC3113229

Genes

DMD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chemical treatment enhances skipping of a mutated exon in the dystrophin gene.PMID 21556062Read ↗

Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and ChallengesSemantic proximity Read ↗

Gene therapy review: Duchenne muscular dystrophy case study.Semantic proximity Read ↗

Redirecting splicing to address dystrophin mutations: molecular by-pass surgery.Semantic proximity Read ↗

Exon-Skipping in Duchenne Muscular Dystrophy.Semantic proximity Read ↗

Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies.Semantic proximity Read ↗

Dantrolene Enhances Antisense-Mediated Exon Skipping in Human and Mouse Models of Duchenne Muscular DystrophySemantic proximity Read ↗

Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues.Semantic proximity Read ↗

Exon skipping therapy for Duchenne muscular dystrophy.Semantic proximity Read ↗

Restoring Dystrophin Expression in Duchenne Muscular Dystrophy MuscleSemantic proximity Read ↗

Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.Semantic proximity Read ↗

Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy.Semantic proximity Read ↗

Emerging genetic therapies to treat Duchenne muscular dystrophy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.